BIOINVENT INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.15 SEK | +1.62% |
|
+6.12% | +32.65% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 613.2 | 1,753 | 2,701 | 2,082 | 1,248 | 1,655 | - | - |
| Enterprise Value (EV) 1 | 459.2 | 1,024 | 1,619 | 1,594 | 1,011 | 1,335 | 161.4 | 1,655 |
| P/E ratio | -3.94 x | -17.3 x | -8.99 x | -46.4 x | -3.78 x | -6.4 x | 2.58 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.54 x | 11.9 x | 139 x | 6.38 x | 17.5 x | 26 x | 1.38 x | 4.43 x |
| EV / Revenue | 4.9 x | 6.95 x | 83.5 x | 4.89 x | 14.2 x | 21 x | 0.13 x | 4.43 x |
| EV / EBITDA | -3.64 x | -16.1 x | -6.14 x | -44 x | -2.86 x | -2.88 x | 0.27 x | 37.1 x |
| EV / FCF | -3,552,270 x | -14,773,420 x | -6,246,688 x | -29,739,137 x | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | -0% | - | - | - | - |
| Price to Book | 3.62 x | 2.43 x | 1.98 x | 1.3 x | 0.95 x | 1.55 x | 0.91 x | - |
| Nbr of stocks (in thousands) | 20,071 | 38,200 | 58,471 | 64,968 | 65,804 | 65,804 | - | - |
| Reference price 2 | 30.55 | 45.90 | 46.20 | 32.05 | 18.96 | 25.15 | 25.15 | 25.15 |
| Announcement Date | 2/27/20 | 2/23/21 | 2/23/22 | 2/22/23 | 2/22/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 93.7 | 147.4 | 19.38 | 326.1 | 71.46 | 63.6 | 1,202 | 373.5 |
| EBITDA 1 | -126.2 | -63.47 | -263.7 | -36.2 | -353.6 | -464.4 | 598.6 | 44.6 |
| EBIT 1 | -137.8 | -75.47 | -278.4 | -50.92 | -370.4 | -464.4 | 598.4 | 44.6 |
| Operating Margin | -147.12% | -51.21% | -1,435.98% | -15.61% | -518.33% | -730.19% | 49.78% | 11.94% |
| Earnings before Tax (EBT) 1 | -138.6 | -76.33 | -278.4 | -42.5 | -329.9 | -535.4 | 669.3 | 157.4 |
| Net income 1 | -138.6 | -76.33 | -278.4 | -42.5 | -330.1 | -963.7 | 510.9 | 48.6 |
| Net margin | -147.92% | -51.8% | -1,436.46% | -13.03% | -461.97% | -1,515.25% | 42.5% | 13.01% |
| EPS 2 | -7.750 | -2.660 | -5.140 | -0.6900 | -5.020 | -3.927 | 9.737 | - |
| Free Cash Flow | -129.3 | -69.32 | -259.1 | -53.6 | - | - | - | - |
| FCF margin | -137.96% | -47.04% | -1,336.68% | -16.44% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/23/21 | 2/23/22 | 2/22/23 | 2/22/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.903 | 16.66 | 270.9 | 17.92 | 20.64 | 16.25 | 13.1 | 26.8 | 15.32 |
| EBITDA 1 | -75.16 | -64.81 | 169.4 | -65.51 | -75.24 | -77.08 | -92.66 | -77.08 | -106.3 |
| EBIT 1 | -78.85 | -68.29 | 165.8 | -69.15 | -79.26 | -80.94 | -96.75 | -81.32 | -110.9 |
| Operating Margin | -1,608.14% | -409.92% | 61.2% | -385.89% | -384.03% | -498.12% | -738.85% | -303.46% | -723.96% |
| Earnings before Tax (EBT) 1 | -78.76 | -67.75 | 167.4 | -63.87 | -78.34 | -73.73 | -88.35 | -71.07 | -96.77 |
| Net income 1 | -78.76 | -67.75 | 167.4 | -63.87 | -78.34 | -73.73 | -88.35 | -71.07 | -96.98 |
| Net margin | -1,606.36% | -406.68% | 61.81% | -356.41% | -379.53% | -453.74% | -674.66% | -265.2% | -633.04% |
| EPS 2 | -1.350 | -1.160 | 2.860 | -1.000 | -1.210 | -1.120 | -1.340 | -1.080 | -1.480 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/23/22 | 4/27/22 | 8/25/22 | 10/27/22 | 2/22/23 | 4/26/23 | 8/30/23 | 10/26/23 | 2/22/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 154 | 729 | 1,083 | 488 | 236 | 320 | 1,494 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -129 | -69.3 | -259 | -53.6 | - | - | - | - |
| ROE (net income / shareholders' equity) | -80% | -16.7% | - | - | - | - | 44.3% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 8.450 | 18.90 | 23.40 | 24.70 | 19.90 | 16.20 | 27.70 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 3.84 | 6.7 | 13.3 | - | - | - | - | - |
| Capex / Sales | 4.1% | 4.55% | 68.41% | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/23/21 | 2/23/22 | 2/22/23 | 2/22/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
25.15
SEK
Average target price
83
SEK
Spread / Average Target
+230.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.65% | 151M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BINV Stock
- Financials BioInvent International AB
